These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 14695693)
1. New antiviral therapies for hepatitis C. O'Leary J; Chung RT Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):265-74. PubMed ID: 14695693 [No Abstract] [Full Text] [Related]
2. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491 [No Abstract] [Full Text] [Related]
3. New therapeutic prospects in HCV treatment. Almasio PL; Ingrassia D; Vergara B; Filosto S Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890 [No Abstract] [Full Text] [Related]
4. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Feld JJ; Hoofnagle JH Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837 [TBL] [Abstract][Full Text] [Related]
5. New therapeutic options for hepatitis C. Waters L; Nelson M Curr Opin Infect Dis; 2006 Dec; 19(6):615-22. PubMed ID: 17075339 [TBL] [Abstract][Full Text] [Related]
6. Tailoring antiviral therapy in hepatitis C. Davis GL Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667 [No Abstract] [Full Text] [Related]
7. Worth the wait. New, more effective therapies for hepatitis C are on the way. Learned J Posit Aware; 2011; 23(1):15-8. PubMed ID: 21314021 [No Abstract] [Full Text] [Related]
8. Prediction of relapse following treatment for hepatitis C: is whole blood more than the sum of its parts? Shire N; Koziel MJ Clin Infect Dis; 2004 Dec; 39(12):1761-3. PubMed ID: 15578396 [No Abstract] [Full Text] [Related]
9. The hepatitis C virus life cycle as a target for new antiviral therapies. Pawlotsky JM; Chevaliez S; McHutchison JG Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890 [TBL] [Abstract][Full Text] [Related]
10. Current and future concepts in hepatitis C therapy. Pawlotsky JM Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999 [TBL] [Abstract][Full Text] [Related]
12. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals. Fanning LJ J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751 [No Abstract] [Full Text] [Related]
13. Challenges and successes in developing new therapies for hepatitis C. De Francesco R; Migliaccio G Nature; 2005 Aug; 436(7053):953-60. PubMed ID: 16107835 [TBL] [Abstract][Full Text] [Related]
14. Treatment and vaccination for hepatitis C: present and future. Jawaid A; Khuwaja AK J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus (HCV) therapies special thematic issue: call for papers. Georg GI; Wang S J Med Chem; 2013 Jan; 56(2):387. PubMed ID: 23294104 [No Abstract] [Full Text] [Related]
16. [BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline]. Schmitz J Pharm Unserer Zeit; 2011 Jan; 40(1):8-9. PubMed ID: 21194074 [No Abstract] [Full Text] [Related]
17. Novel hepatitis C drugs in current trials. Kronenberger B; Welsch C; Forestier N; Zeuzem S Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427 [TBL] [Abstract][Full Text] [Related]
18. The design of drugs for HIV and HCV. De Clercq E Nat Rev Drug Discov; 2007 Dec; 6(12):1001-18. PubMed ID: 18049474 [TBL] [Abstract][Full Text] [Related]
19. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence. Watashi K; Metselaar HJ; van der Laan LJ Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373 [No Abstract] [Full Text] [Related]
20. The way forward in HCV treatment--finding the right path. Manns MP; Foster GR; Rockstroh JK; Zeuzem S; Zoulim F; Houghton M Nat Rev Drug Discov; 2007 Dec; 6(12):991-1000. PubMed ID: 18049473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]